-
Aquestive Therapeutics: A Significant Step Forward in Regulatory Development
NASDAQ: AQST Investors and stakeholders interested in the pharmaceutical landscape have a compelling reason to examine the latest announcement from Aquestive Therapeutics. The news release, accessible at https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-regulatory-development, signals a crucial milestone in the company’s journey toward bringing innovative therapies to market. Understanding the Context of the Announcement Aquestive Therapeutics operates within the specialized field…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…